|1.||Taketani, Shigeru: 8 articles (01/2013 - 05/2002)|
|2.||Schneider-Yin, X: 7 articles (11/2010 - 08/2000)|
|3.||Deybach, Jean-Charles: 6 articles (01/2015 - 01/2002)|
|4.||Gouya, Laurent: 6 articles (01/2015 - 01/2002)|
|5.||Bloomer, Joseph R: 6 articles (07/2011 - 06/2002)|
|6.||Elder, G H: 6 articles (03/2010 - 12/2001)|
|7.||Deybach, J C: 6 articles (01/2009 - 08/2000)|
|8.||Minder, E I: 5 articles (11/2010 - 10/2000)|
|9.||Badminton, Michael N: 5 articles (03/2009 - 01/2006)|
|10.||Gouya, L: 5 articles (01/2009 - 08/2000)|
|1.||Conversion Disorder (Astasia Abasia)
09/01/2007 - "To study the mutations in the ferrochelatase gene (FECH) and the phenotypic expression of erythropoietic protoporphyria (EPP) in a group of Spanish patients. "
06/01/2001 - "New missense mutation in the human ferrochelatase gene in a family with erythropoietic protoporphyria: functional studies and correlation of genotype and phenotype."
01/15/2015 - "Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites."
04/03/2014 - "In 90% of people with erythropoietic protoporphyria (EPP), the disease results from the inheritance of a common hypomorphic FECH allele, encoding ferrochelatase, in trans to a private deleterious FECH mutation. "
10/01/2013 - "Erythropoietic protoporphyria (EPP) results from partial deficiency of ferrochelatase (FECH). "
01/01/1980 - "Studies on the mechanism of experimental porphyria and ferrochelatase inhibition produced by 3,5-diethoxycarbonyl-1,4-dihydrocollidine."
08/01/2006 - "The nature of the remaining ferrochelatase allele was examined by polymorphism analysis and we discuss the insights that this patient's genotype may reveal about the pathogenesis of porphyria in myelodysplasia."
08/01/2006 - "As chromosome 18 is the locus of the ferrochelatase gene, we postulate that this chromosomal deletion led to reduced synthesis of the enzyme in the bone marrow clone, so causing the porphyria. "
11/12/1993 - "The sensitivity of different species to ETC-induced porphyria correlated with the effect of ETC on hepatic ferrochelatase activity. "
01/01/1979 - "This supports the contention that the enzyme is deficient in PV and that an inactive ferrochelatase is the primary deficiency in this type of porphyria."
12/10/2002 - "Cutaneous tumors were exposed to various doses of ferrochelatase enzyme inhibitor (lead) and to different durations and doses of visible light. "
08/01/1992 - "Enzyme measurements showed a threefold decrease in ferrochelatase activity in tumors compared with livers (P less than 0.001). "
10/31/1991 - "c) The presence of hepatic DENA induced tumors could diminish basal hepatic ferrochelatase activity. "
11/01/1999 - "Ferrochelatase, a novel target for photodynamic therapy of cancer."
11/01/1999 - "This study was designed to investigate the hypothesis that the inhibition of ferrochelatase will cause in situ build up of high concentrations of protoporphyrin-IX which may act as a putative agent for photodestruction of cancer cells. "
02/01/2003 - "Proteobacteria-like ferrochelatase in the malaria parasite."
01/01/2013 - "To study the role of the dual heme sources in malaria parasite growth and development, we knocked out the first enzyme, δ-aminolevulinate synthase (ALAS), and the last enzyme, ferrochelatase (FC), in the heme-biosynthetic pathway of Plasmodium berghei (Pb). "
|4.||Messenger RNA (mRNA)
|6.||Transferrin Receptors (Transferrin Receptor)
|8.||Hydroxymethylbilane Synthase (Porphobilinogen Deaminase)
|9.||Protoporphyrinogen Oxidase (Protox)
|10.||Complementary DNA (cDNA)
|1.||Photochemotherapy (Photodynamic Therapy)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)